sj-pdf-1-cep-10.1177_03331024231222923 - Supplemental material for Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies

Supplemental material, sj-pdf-1-cep-10.1177_03331024231222923 for Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies by Marta Torres-Ferrús, Victor J. Gallardo, Alicia Alpuente, Edoardo Caronna, Eulalia Giné-Ciprés and Patricia Pozo-Rosich in Cephalalgia</p

sj-jpg-4-cep-10.1177_03331024231170807 - Supplemental material for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

Supplemental material, sj-jpg-4-cep-10.1177_03331024231170807 for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study by Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling and Patricia Pozo-Rosich in Cephalalgia</p

sj-jpg-5-cep-10.1177_03331024231170807 - Supplemental material for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

Supplemental material, sj-jpg-5-cep-10.1177_03331024231170807 for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study by Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling and Patricia Pozo-Rosich in Cephalalgia</p

sj-jpg-3-cep-10.1177_03331024231170807 - Supplemental material for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

Supplemental material, sj-jpg-3-cep-10.1177_03331024231170807 for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study by Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling and Patricia Pozo-Rosich in Cephalalgia</p

sj-jpg-2-cep-10.1177_03331024231170807 - Supplemental material for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

Supplemental material, sj-jpg-2-cep-10.1177_03331024231170807 for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study by Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling and Patricia Pozo-Rosich in Cephalalgia</p

sj-pdf-1-cep-10.1177_03331024221123081 - Supplemental material for Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey

Supplemental material, sj-pdf-1-cep-10.1177_03331024221123081 for Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey by Irene de Boer, Anna Ambrosini, Rashmi B Halker Singh, Betül Baykan, Dawn C Buse, Cristina Tassoreli, Rigmor H Jensen, Patricia Pozo-Rosich and Gisela M Terwindt in Cephalalgia</p

sj-pdf-1-cep-10.1177_03331024231214987 - Supplemental material for Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study

Supplemental material, sj-pdf-1-cep-10.1177_03331024231214987 for Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study by Messoud Ashina, Dimos D. Mitsikostas, Faisal Mohammad Amin, Pinar Kokturk, Christoph J. Schankin, Gurdal Sahin, Patricia Pozo-Rosich, Paul J. Dorman, Tomáš Nežádal, Anne Christine Poole, Isabel Pavão Martins, Marja-Liisa Sumelahti, Verena Ramirez Campos, Andrew H. Ahn, Leonidas Lyras and Cristina Tassorelli in Cephalalgia</p